Clear Ideas by Rene MagritteAs Nina’s scientific consultant( and partner ), I have agreed to help her navigate the incredibly complex and ever-changing efforts in world-wide development of a Covid-1 9 vaccine. It is astounding to see that there are over 30 inoculation candidates currently under various the stages of clinical tribulations, with more to reach this stage in the upcoming months. Some of these efforts I will not concentrates on for various reasonablenes, as countless vaccine nominees are being developed by countries, like china and Russia, from which information is not especially forthcoming, or in very small companies that are unlikely to be able to reach the capacity for world-wide delivery. But even for those working inoculations that I will focus on–the inoculations developed under the US and Europe–in the US, the timeline for their favor by the Food and Drug Administration has been politicized and undermined by the Trump administration.
It seems now more than ever we need to have clear and unfettered information on the design, efficacy, and safety of these brand-new vaccines. This is especially true given the unprecedented moved at which these inoculations are being developed, even to the point where we have overlapping clinical stages in progress and manufacturing capability being built before FDA approval. While I am not an expert in inoculations, my background in pharmaceutical chemistry and therapeutic drug progress gives me a rational vantage point to assess what’s fact or story, and what looks like a good inoculation that I personally would have no qualms taking. I still retain over 20 years ago when I was working with a company on the specific characteristics of a vaccine for bacterial meningitis. The administrator of the program told me that there were three critical issues in a vaccine pattern I needed to be done: safety, security, and security! Of route, the inoculation must be done, but refuge is the primary concern because this will be given to individuals who are currently health but who may( or may not) encounter this disease in their future.
So here is my promise to you: I will share whatever information I have in the future about the Covid-1 9 vaccines being developed that I analyse to be serious challengers for safe and efficient vaccines and also those that I do not believe to have been adequately vetted for safety. And as I fix government decisions for myself and my family about which vaccine to take and when, I will share that information with you as well. Many of our friends and relatives have been very reassured by the fact that they have me to turn to when the time comes to make a decision about the security concerns of a Covid-1 9 inoculation, so Nina and I thought you said you in the Yoga for Healthy Aging community might also feel the same way.
Brad Gibson, Ph.D ., is our behind-the-scenes scientific consultant, who still writes unusually sometimes. As a former Professor at the Buck Institute for Research on Aging, Brad’s work was focused on understanding the biological and chemical treats that are common to both age-related diseases and aging. Prior to that he was a Professor of Pharmaceutical Chemistry at UCSF from 1985 -2 000, where he worked on various biomedical research projects including infectious diseases and structural biology. Brad joined Amgen in 2016, a California-based biotechnology and pharmaceutical company, where he is currently a Director of Therapeutic Discovery. Brad received his PhD in Analytical Chemistry from the Massachusetts Institute of Technology in 1984 and then made a postdoctoral fellowship in Chemistry at Cambridge University in England before joining the faculty at UCSF in 1985.
Subscribe to Yoga for Healthy Aging by Email deg Follow Yoga for Healthy Aging on Facebook deg To degree Yoga for Healthy Aging: A Guide to Lifelong Well-Being, go to Amazon, Shambhala, Indie Bound or your local bookstore.
Read more: yogaforhealthyaging.blogspot.com